donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

INDP Indaptus Therapeutics

2.470
-0.120-4.63%
Close 08/19 16:00 ET
High
2.690
Open
2.490
Turnover
14.20K
Low
2.438
Pre Close
2.590
Volume
5.64K
Market Cap
20.40M
P/E(TTM)
Loss
52wk High
28.830
Shares
8.26M
P/E(Static)
Loss
52wk Low
1.890
Float Cap
11.40M
Bid/Ask %
0.00%
Historical High
24760.000
Shs Float
4.62M
Volume Ratio
0.27
Historical Low
1.890
Dividend TTM
--
Div Yield TTM
--
P/B
0.67
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.12%
Amplitude
9.74%
Avg Price
2.515
Lot Size
1
Float Cap
11.40M
Bid/Ask %
0.00%
Historical High
24760.000
Shs Float
4.62M
Volume Ratio
0.27
Historical Low
1.890
Dividend TTM
--
P/B
0.67
Dividend LFY
--
Turnover Ratio
0.12%
Amplitude
9.74%
Avg Price
2.515
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...